MedPath

Identification of Gene and Protein Markers of Kidney Injury in Aminoglycoside-treated Children

Completed
Conditions
Infection
Renal Dysfunction
Interventions
Drug: aminoglycoside
Registration Number
NCT00308906
Lead Sponsor
Virginia Commonwealth University
Brief Summary

The purposes of this study are to identify potential gene and protein markers of aminoglycoside-induced kidney injury in infants, children and adolescents treated with aminoglycoside antibiotics.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
166
Inclusion Criteria

(1) Hospitalized male and female newborns, infants, children and adolescents (ages birth to 18 years) with a diagnosis of suspected or proven bacterial sepsis, meningitis or other indication necessitating aminoglycoside therapy (2) hospitalized and outpatient newborns, infants, children and adolescents (ages birth to 18 years) who are not receiving aminoglycoside therapy.

Exclusion Criteria

(1) Current treatment with inhaled or ophthalmic aminoglycosides (2) Prior treatment with an aminoglycoside within the last 30 days

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
2aminoglycosideAminoglycoside treated infants and children without renal injury
1aminoglycosideHospitalized, untreated infants and children
3aminoglycosideAminoglycoside treated infants with renal injury
Primary Outcome Measures
NameTimeMethod
Indicators of renal injuryPre and post treatment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

University of Lousiville

🇺🇸

Louisville, Kentucky, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath